Omega Therapeutics to Participate in the Jefferies Healthcare Conference and Goldman Sachs 43rd Annual Global Healthcare Conference in June 2022

CAMBRIDGE, Mass., June 2, 2022 /PRNewswire/ -- Omega Therapeutics, Inc. (Nasdaq: OMGA) ("Omega"), a development-stage biotechnology company pioneering the first systematic approach to use mRNA therapeutics as programmable epigenetic medicines by leveraging its OMEGA Epigenomic Programing™ platform, today announced that Mahesh Karande, President and CEO, will participate in fireside chats at the following upcoming investor conferences in June.

Jefferies Healthcare Conference
Date: June 10, 2022
Time: 9:30 a.m. ET

Goldman Sachs 43rd Annual Global Healthcare Conference
Date: June 15, 2022
Time: 5:40 p.m. ET / 2:40 p.m. PT

Live webcasts of the fireside chats will be available on the Investors & Media section of the Company's website at www.omegatherapeutics.com. An archived replay of the fireside chats will be available on the same website for approximately 90 days.

Omega Therapeutics, founded by Flagship Pioneering, is a development-stage biotechnology company pioneering the first systematic approach to use mRNA therapeutics as a new class of programmable epigenetic medicines. The company's OMEGA Epigenomic Programming™ platform harnesses the power of epigenetics, the mechanism that controls gene expression and every aspect of an organism's life from cell genesis, growth, and differentiation to cell death. Using a suite of technologies, paired with Omega's process of systematic, rational, and integrative drug design, the deterministic OMEGA platform enables control of fundamental epigenetic processes to correct the root cause of disease by returning aberrant gene expression to a normal range without altering native nucleic acid sequences. Omega's modular and programmable mRNA epigenetic medicines, Omega Epigenomic Controllers™, target specific epigenomic loci within insulated genomic domains, EpiZips™, from amongst thousands of unique, mapped, and validated genome-wide DNA-sequences, with high specificity to durably tune single or multiple genes to treat and cure diseases through Precision Genomic Control™. Omega is currently advancing a broad pipeline of development candidates spanning a range of disease areas, including oncology, regenerative medicine, multigenic diseases including immunology, and select monogenic diseases.

For more information, visit omegatherapeutics.com, or follow us on Twitter and LinkedIn.

Media contact:
Jason Braco
LifeSci Communications
646.751.4361
[email protected] 

Investor contact:
Kevin Murphy
Argot Partners
212.600.1902
[email protected] 

SOURCE Omega Therapeutics